Cuisset, Thomas <br/><br/>
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).  [electronic resource] 

 -  JACC. Cardiovascular interventions  Aug 2013 
 - 854-63 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1876-7605 
<br/><br/><label>Standard No.: </label>10.1016/j.jcin.2013.04.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--blood<br/>Aged<br/>Aged, 80 and over<br/>Area Under Curve<br/>Biomarkers--blood<br/>Cell Adhesion Molecules--blood<br/>Clopidogrel<br/>Coronary Thrombosis--blood<br/>Drug Resistance<br/>Female<br/>Hemorrhage--blood<br/>Humans<br/>Logistic Models<br/>Male<br/>Microfilament Proteins--blood<br/>Middle Aged<br/>Multivariate Analysis<br/>Odds Ratio<br/>Percutaneous Coronary Intervention--adverse effects<br/>Phosphoproteins--blood<br/>Phosphorylation<br/>Piperazines--adverse effects<br/>Platelet Activation--drug effects<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Function Tests<br/>Prasugrel Hydrochloride<br/>Prospective Studies<br/>ROC Curve<br/>Risk Assessment<br/>Risk Factors<br/>Thiophenes--adverse effects<br/>Ticlopidine--adverse effects<br/>Time Factors<br/>Treatment Outcome<br/>Vasodilator-Stimulated Phosphoprotein